LINK POSTED ON STOCKTWITS
The Fly On The Wall
SAGE 10:47 BMO expects SAGE's positive stock momentum to continue BMO Capital analyst Gary Nachman views the Phase 2 severe postpartum depression data from SAGE Therapeutics as "impressive and better than most anticipated." SAGE-547 showed a very clear signal that it has durable activity in postpartum depression and the data justify moving forward aggressively with the program, Nachman tells investors in a research note. SAGE-547 is a "potential game changer" for SAGE as there are no currently approved therapies specifically indicated for postpartum depression, the analyst contends. He expects the stock's positive momentum to continue and keeps an Outperform rating on SAGE.